Ken Griffin Caribou Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.56 - $2.73 $38,688 - $67,704	24,800 Added 137.78%	42,800 $83,000
Q2 2024 Aug 14, 2024	SELL	$1.62 - $5.05 $4,050 - $12,625	-2,500 Reduced 12.2%	18,000 $29,000
Q1 2024 May 15, 2024	SELL	$4.82 - $8.26 $26,028 - $44,604	-5,400 Reduced 20.85%	20,500 $105,000
Q4 2023 Feb 14, 2024	BUY	$3.58 - $6.25 $12,172 - $21,250	3,400 Added 15.11%	25,900 $148,000
Q3 2023 Nov 14, 2023	BUY	$4.08 - $8.14 $50,592 - $100,936	12,400 Added 122.77%	22,500 $107,000
Q2 2023 Aug 14, 2023	BUY	$4.04 - $5.47 $16,564 - $22,427	4,100 Added 68.33%	10,100 $42,000
Q1 2023 May 15, 2023	SELL	$4.3 - $7.78 $43,430 - $78,578	-10,100 Reduced 62.73%	6,000 $31,000
Q4 2022 Feb 14, 2023	SELL	$5.57 - $11.01 $337,542 - $667,206	-60,600 Reduced 79.01%	16,100 $101,000
Q3 2022 Nov 14, 2022	SELL	$5.34 - $12.79 $223,212 - $534,622	-41,800 Reduced 35.27%	76,700 $809,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.